PurMinds NeuroPharma Appoints Vanessa Williamson as Chief Business Officer

Toronto, Ontario and Boston, Massachusetts--(Newsfile Corp. - May 23, 2024) - PurMinds NeuroPharma ("PurMinds™" or the "Company"), a clinical-stage neuroscience company focused on advancing a robust pipeline of small molecules, psychedelic compounds, and other modalities for the treatment of neurological and neurodegenerative disorders, today announced that Vanessa Williamson has joined the company as Chief Business Officer effective May 20, 2024.

"We are thrilled to welcome Vanessa to the PurMinds leadership team during this pivotal stage of our growth," said Janet Qi, CPA. MBA. Co-Founder & Chief Executive Officer of PurMinds NeuroPharma. "Her impressive track record in forging strategic alliances, fundraising success, and fostering innovation ecosystems will be invaluable as we accelerate the development of our breakthrough therapies and explore new avenues for value creation."

Prior to joining PurMinds, Williamson held executive roles at companies such as SQI Diagnostics Systems, Inc., Precision BioMonitoring, Inc., and the Ontario Centres of Excellence among others. She has a proven ability to identify and execute upon unexpected opportunities, establishing win-win partnerships and strategic alliances that drive corporate growth and exceed stakeholder expectations.

"I am excited to join the pioneering team at PurMinds and contribute my expertise to advance their groundbreaking work in neuroscience," said Williamson. "PurMinds' innovative approach to developing novel therapies for neurological and neurodegenerative disorders has the potential to transform lives, and I look forward to supporting the company's mission through strategic collaborations and partnerships."

ABOUT PURMINDSTM

PurMinds™ is a neurological drug development company pursuing breakthrough solutions to neurological and neurodegenerative disorders. Its clinical pipeline includes innovative therapeutics that combine proven mechanisms of action with the powerful ability of psychedelics and other neuroplastogens to rapidly promote neuroplasticity and neuro-rejuvenation. The company's Ontario NeuroLab and Production Facility was granted a Health Canada approved Dealer's License for Controlled Drugs and Substances authorizing the production, formulation and global supply of pharma-grade Psychedelic compounds including Psilocybin and MDMA for clinical trials and research studies. PurMinds™ champions a de-risked business model that includes a multi-modal approach to drug development, progressing long-term value creation through the accelerated development of novel therapeutics, accompanied by short and mid-term revenue paths. PurMinds™ is headquartered in Toronto, ON Canada with offices in Montreal, QC and Boston, MA USA. For further information about PurMinds™ NeuroPharma, please visit the Company's website at PurMinds.com.

Forward-Looking Statements
This press release contains forward-looking statements. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to known and unknown risks, uncertainties and assumptions and accordingly, actual results and future events could differ materially from those expressed or implied in such statements. You are hence cautioned not to place undue reliance on forward-looking statements. All statements other than statements of present or historical fact are forward-looking statements, including statements with respect to PurMinds™' future business plans and partnerships. Forward-looking statements include words or expressions such as "proposed", "anticipated", "will", "subject to", "near future", "in the event", "would", "expect", "prepared to" and other similar words or expressions and include, but are not limited to: the ability of PurMinds™ to secure patent protection; the regulatory environment in which PurMinds™ operates; the ability of PurMinds™ to carry out its business plans and unforeseen challenges in carrying out such plans; trends in the future use of psychedelics; general business, economic, competitive, political and social uncertainties; the state of capital markets; and other unforeseen events, developments, or factors causing any of the aforesaid expectations, assumptions, and other factors ultimately being inaccurate or irrelevant. The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We disclaim any obligation to update or revise these forward-looking statements, except as required by applicable law.

PR Contact
Kristina Spionjak
pr@hlthcommunications.com

SOURCE: PurMinds NeuroPharma

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/210075